Nycomed Faces IP Suit Over Solaraze Gel
Ontario, Canada-based GlycoBioSciences lodged its suit in the U.S. District Court for the Eastern District of New York, targeting Nycomed, Nycomed subsidiary Pharmaderm and Jagotec AG.
The defendants make and sell Solaraze, a treatment for the chronic skin condition actinic keratosis, the complaint states.
Melville, N.Y.-based Nycomed holds the new drug application for Solaraze, and exclusively licenses six Solaraze...
To view the full article, register now.